Catalyst Dossier · compiled by CeliA 🧫
Johnson & Johnson (JNJ)
Pharmaceutical Preparations · market cap $549.8B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-13
Earnings
Pipeline
20
programs
Upcoming events
7
next 90d+
Dossier
Ready
cached
Johnson & Johnson is a mega-cap pharmaceutical and medical technology conglomerate headquartered in New Brunswick, NJ, ranked No. 48 on the 2025 Fortune 500 with one of only two AAA credit ratings among U.S. corporates. With a $618B market cap and ~$94B in 2025 revenue, J&J operates a broad pipeline spanning oncology, CNS, infectious disease, and pain, with near-term catalysts anchored by a Phase 3 nipocalimab readout (estimated May 2027, importance 9/10) and a Phase 2 amivantamab IV update. A Phase 3 catalyst turned positive on June 30, 2026, and Q2 2026 earnings are due July 15.
The catalyst path
- 2026-10-13Earningsimp 5/10
- 2027-04-27 (est.)Phase 2 · Amivantamab IVimp 7/10
- 2027-05-14 (est.)Phase 3 · Nipocalimabimp 9/10
- 2027-07-30 (est.)Phase 3 · Talquetamabimp 9/10
- 2027-07-30 (est.)Phase 3 · Daratumumabimp 9/10
- 2027-08-15 (est.)Phase 2 · Oral Dexamethasoneimp 7/10
- 2027-08-15 (est.)Phase 2 · Talquetamabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| galantamine ER | Phase 3 | Alzheimer's Disease |
| R228060 | Phase 2 | Major Depressive Disorder |
| Test acetaminophen | Phase 3 | Post-operative Dental Pain |
| CG 5503;tapentadol | Phase 3 | Osteoarthritis |
| tapentadol (CG5503) ER | Phase 3 | Low Back Pain |
| JNJ-90301900 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| Experimental Product 1% Colloidal Oatmeal Balm | Phase 2 | Atopic Dermatitis |
| levofloxacin | Phase 3 | Pneumonia |
| JNJ16269110 | Phase 2 | Diabetes Mellitus, Type 2 |
| Rivaroxaban | Phase 3 | Atrial Fibrillation |
| ibuprofen; pseudoephedrine HCl | Phase 2 | Enuresis |
| tapentadol (CG5503) Immediate Release IR | Phase 3 | Low Back Pain |
| Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | Pain |
| Paliperidone extended-release | Phase 3 | Bipolar Disorder |
| Risperdal Consta | Phase 3 | Bipolar Disorder |
| Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD) | Phase 3 | Multiple Myeloma |
| paliperidone ER Oros | Phase 3 | Schizophrenia |
| Gemcitabine with R115777 | Phase 3 | Pancreatic Neoplasms |
| tapentadol HCl | Phase 2 | Pain |
| Mebendazole | Phase 3 | Healthy Volunteers |
Price & technical context
3-month
+18.2%
6-month
+13.6%
12-month
+52.4%
52-wk range
$174.16–$278.43
vs 50-day MA
+2.5%
vs 200-day MA
+13.1%
Realized vol
19.0%
Max drawdown
-15.1%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for JNJ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.